You can buy or sell Repligen and other stocks, options, ETFs, and crypto commission-free!
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). Read More The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 10
Edited Transcript of RGEN earnings conference call or presentation 9-May-19 12:30pm GMT
Q1 2019 Repligen Corp Earnings Call WALTHAM May 10, 2019 (Thomson StreetEvents) -- Edited Transcript of Repligen Corp earnings conference call or presentation Thursday, May 9, 2019 at 12:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Anthony J. Hunt Repligen Corporation - CEO, President, Director & Member of Scientific Advis...
Yahoo FinanceMay 9
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks.
Yahoo FinanceMay 9
Repligen: 1Q Earnings Snapshot
WALTHAM, Mass. (AP) _ Repligen Corp. (RGEN) on Thursday reported first-quarter profit of $8.1 million. The Waltham, Massachusetts-based company said it had net income of 17 cents per share. Earnings, adjusted for one-time gains and costs, came to 28 cents per share. The drug developer posted revenue of $60.6 million in the period. Repligen expects full-year earnings in the range of 84 cents to 90 cents per share. Repligen shares have risen 28% since the beginning of the year. The stock has climbed 67% i...
Expected Aug 1, Pre-Market